What is AliveCor?
AliveCor, Inc. is a prominent medical software company that has redefined the accessibility of cardiac diagnostics. By developing innovative hardware such as the KardiaMobile 6L and the KardiaMobile Card, the company enables users to record medical-grade EKGs anywhere and at any time. These devices, paired with the KardiaCare platform, provide users with the power to detect six of the most common arrhythmias, effectively bridging the gap between clinical-grade diagnostics and consumer-friendly mobile technology. Headquartered in Mountain View, California, the company has established itself as a leader in the intersection of mobile computing and cardiology.
How much funding has AliveCor raised?
AliveCor has raised a total of $154.6M across 7 funding rounds:
Series A
$3.3M
Series B
$10.5M
Series C
$20M
Series D
$30M
Debt
$20M
Other Financing Round
$5.8M
Series E
$65M
Series A (2011): $3.3M with participation from Oklahoma Life Science Fund, Qualcomm Ventures, and Burrill & Co.,
Series B (2012): $10.5M led by Khosla Ventures, Qualcomm Ventures, Burrill & Co.,, and Oklahoma Life Science Fund
Series C (2016): $20M supported by WP Global Partners
Series D (2017): $30M featuring Mayo Clinic and Omron Healthcare
Debt (2019): $20M backed by Oxford Finance
Other Financing Round (2019): $5.8M, investors not publicly disclosed
Series E (2020): $65M led by WP Global Partners, BOLD Capital Partners, Qualcomm Ventures, Khosla Ventures, and OMRON Corporation
Key Investors in AliveCor
Qualcomm Ventures
A global technology firm that develops advanced semiconductor and wireless communication solutions, focusing on accelerating the adoption of next-generation connectivity and intelligent computing.
Khosla Ventures
A venture capital firm providing strategic advice and assistance to entrepreneurs working on breakthrough technologies across health, AI, and enterprise sectors.
BOLD Capital Partners
A venture capital firm dedicated to investing in transformative technologies and entrepreneurs who aim to disrupt large markets and address significant global challenges.
What's next for AliveCor?
With the support of its latest capital injection, AliveCor is well-positioned to further integrate its diagnostic tools into the broader healthcare ecosystem. The company is expected to focus on enhancing its algorithmic capabilities for arrhythmia detection and expanding its strategic partnerships with global health organizations. By leveraging its existing infrastructure and the backing of high-profile investors, AliveCor aims to continue its trajectory of democratizing heart health monitoring, potentially exploring new frontiers in preventative medicine and remote patient management systems.
See full AliveCor company page
